期刊
CLINICA CHIMICA ACTA
卷 421, 期 -, 页码 51-56出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2013.02.005
关键词
Apolipoprotein B48; Remnant lipoprotein; Coronary artery disease; Hyperlipidemia Restenosis; LDL cholesterol
资金
- Grants-In-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of japan
- Senshin Medical Research Foundation
- VRI Research Grant from AstraZeneca
- Grants-in-Aid for Scientific Research [23790854, 23590835] Funding Source: KAKEN
Background: To identify new therapeutic targets for coronary artery disease (CAD), we investigated whether fasting serum concentration of apolipoprotein (apo) B48 could be a marker for CAD. Methods: Patients with CAD were divided into those with new-onset CAD [i.e., those receiving percutaneous coronary intervention (PCI) for the first time] and those with chronic CAD (i.e., those receiving follow-up coronary angiography). Fasting serum biochemical analyses were performed on admission and 6 months after the PO. Results: On admission, serum LDL-C concentrations in patients with chronic CAD (n= 138), presumably receiving statin treatment, were lower than in patients with new-onset CAD (n=50, p<0.02) or without CAD (n=71, p<0.001). Nevertheless, apoB48 was higher in CAD patients than in those without CAD (p<0.001). After adjusting for classic cardiovascular risk factors, multivariate logistic regression analyses showed apoB48 to be an independent predictor of coronary risk in new-onset or chronic CAD, irrespective of the LDL-C levels. Moreover, apoB48 was markedly increased during the follow-up period in CAD patients having new lesion progression after the prior PCI Conclusion: Fasting serum apoB48 concentration could be a marker of new onset as well as chronic CAD, and predict new lesion progression in secondary prevention. (C) 2013 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据